JP7254786B2 - ビフィドバクテリウム・アニマリス亜種ラクティス（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ａｎｉｍａｌｉｓ ｓｓｐ．ｌａｃｔｉｓ）を用いて癌を処置するための組成物及び方法 - Google Patents

ビフィドバクテリウム・アニマリス亜種ラクティス（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ａｎｉｍａｌｉｓ ｓｓｐ．ｌａｃｔｉｓ）を用いて癌を処置するための組成物及び方法 Download PDF

Info

Publication number
JP7254786B2
JP7254786B2 JP2020521493A JP2020521493A JP7254786B2 JP 7254786 B2 JP7254786 B2 JP 7254786B2 JP 2020521493 A JP2020521493 A JP 2020521493A JP 2020521493 A JP2020521493 A JP 2020521493A JP 7254786 B2 JP7254786 B2 JP 7254786B2
Authority
JP
Japan
Prior art keywords
lactis
cancer
bifidobacterium animalis
carcinoma
animalis ssp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020521493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526581A5 (enExample
JP2020526581A (ja
Inventor
サンディ，ピーター
パプコフ，ジャックリーヌ
シゾヴァ，マリア
グッドマン，ブライアン
ガードナー，ハンフリー
ポニクテラ，ホリー
ウー，ハンク
カフリー，ウィリアム
デュッタ，アヌプリヤ
Original Assignee
エヴェロ バイオサイエンシズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63036353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7254786(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エヴェロ バイオサイエンシズ，インコーポレーテッド filed Critical エヴェロ バイオサイエンシズ，インコーポレーテッド
Publication of JP2020526581A publication Critical patent/JP2020526581A/ja
Publication of JP2020526581A5 publication Critical patent/JP2020526581A5/ja
Application granted granted Critical
Publication of JP7254786B2 publication Critical patent/JP7254786B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020521493A 2017-07-05 2018-07-05 ビフィドバクテリウム・アニマリス亜種ラクティス（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ａｎｉｍａｌｉｓ ｓｓｐ．ｌａｃｔｉｓ）を用いて癌を処置するための組成物及び方法 Active JP7254786B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762528669P 2017-07-05 2017-07-05
US62/528,669 2017-07-05
PCT/US2018/040841 WO2019010255A1 (en) 2017-07-05 2018-07-05 COMPOSITIONS AND METHODS FOR TREATING CANCER USING BIFIDOBACTERIUM ANIMALIS SSP. LACTIS

Publications (3)

Publication Number Publication Date
JP2020526581A JP2020526581A (ja) 2020-08-31
JP2020526581A5 JP2020526581A5 (enExample) 2021-08-12
JP7254786B2 true JP7254786B2 (ja) 2023-04-10

Family

ID=63036353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020521493A Active JP7254786B2 (ja) 2017-07-05 2018-07-05 ビフィドバクテリウム・アニマリス亜種ラクティス（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ａｎｉｍａｌｉｓ ｓｓｐ．ｌａｃｔｉｓ）を用いて癌を処置するための組成物及び方法

Country Status (12)

Country Link
US (3) US10792314B2 (enExample)
EP (1) EP3648780A1 (enExample)
JP (1) JP7254786B2 (enExample)
KR (1) KR102563191B1 (enExample)
CN (1) CN111356464A (enExample)
AR (1) AR112328A1 (enExample)
AU (1) AU2018298087A1 (enExample)
BR (1) BR112019028301A2 (enExample)
CA (1) CA3068757A1 (enExample)
MA (1) MA51770A (enExample)
TW (1) TW201906620A (enExample)
WO (1) WO2019010255A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2016196605A1 (en) * 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
MD3804737T2 (ro) 2017-06-14 2022-10-31 4D Pharma Res Limited Compoziții care conțin tulpini bacteriene
CN115813955A (zh) 2017-06-14 2023-03-21 4D制药研究有限公司 包含细菌菌株的组合物
TW201906620A (zh) 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法
EP3768285A1 (en) 2018-03-19 2021-01-27 4D Pharma Research Limited Compositions comprising bacterial strains
CA3106139A1 (en) 2018-07-16 2020-01-23 4D Pharma Research Limited Compositions comprising bacterial strains
MA54161A (fr) 2018-12-12 2022-03-23 4D Pharma Res Ltd Compositions comprenant des souches bactériennes parabacteroides pour le traitement du cancer
WO2020252144A1 (en) * 2019-06-11 2020-12-17 Evelo Biosciences, Inc. Secreted microbial extracellular vesicles
WO2021022110A1 (en) 2019-08-01 2021-02-04 Evelo Biosciences, Inc. Inducing immune effects using bacteria of the genus bifidobacterium
KR102357904B1 (ko) * 2019-10-29 2022-02-04 경희대학교 산학협력단 항암용 금 나노입자
CN112618577B (zh) * 2020-12-15 2023-07-25 深圳君拓生物科技有限公司 动物双歧杆菌在提高肿瘤免疫治疗应答中的作用
US20240124905A1 (en) * 2021-01-26 2024-04-18 Cb Therapeutics, Inc. Recombinant Polyprenol Diphosphate Synthases
TW202304415A (zh) * 2021-04-08 2023-02-01 美商艾弗洛生物科技股份有限公司 含有細菌的藥物製劑
CN113368259B (zh) * 2021-06-22 2022-07-22 海南大学 一种基于修饰细菌加载纳米药物的方法及其复合物和在治疗结肠癌中的应用
US20230096810A1 (en) * 2021-09-24 2023-03-30 Johnson & Johnson Consumer Inc. Dosage forms for the delivery of a probiotic
CN114028432A (zh) * 2021-11-05 2022-02-11 上海市第十人民医院 双歧杆菌提升铂类化疗药物敏感性的药物新用途
CN115363094A (zh) * 2021-11-30 2022-11-22 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在预防和/或改善胃炎中的应用
CN114480229B (zh) * 2022-04-15 2022-08-09 微康益生菌(苏州)股份有限公司 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用
CN115216423B (zh) * 2022-06-15 2023-04-25 南昌大学 一种动物双歧杆菌sf及其在医药和食品中的应用
WO2025071560A1 (en) * 2023-09-28 2025-04-03 Rutgers, The State University Of New Jersey Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof
CN117417866B (zh) * 2023-10-27 2026-02-27 江南大学 一种产胆盐水解酶的动物双歧杆菌及其在新生儿黄疸中的应用
CN117327632B (zh) * 2023-12-01 2024-02-13 四川厌氧生物科技有限责任公司 一种动物双歧杆菌及其应用
CN121046519B (zh) * 2025-11-05 2026-03-20 中国食品发酵工业研究院有限公司 动物双歧杆菌乳亚种bl-99的活菌定量检测方法及其引物、探针、试剂盒与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104224851A (zh) 2014-08-15 2014-12-24 任发政 动物双歧杆菌乳酸亚种CGMCC No.9273的应用
JP2016517425A (ja) 2013-03-14 2016-06-16 セラバイオーム，エルエルシー プロバイオティクス生物及び／又は治療剤の標的化胃腸管デリバリー
WO2016196605A1 (en) 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
JP2017514857A (ja) 2014-05-05 2017-06-08 ジョヴァンニ・モーニャＧｉｏｖａｎｎｉ ＭＯＧＮＡ 腫瘍、後天性免疫不全症候群および白血病の二重免疫バイオスティミュレーションによる処置における使用のための治療剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1481681A1 (en) 2003-05-30 2004-12-01 Claudio De Simone Lactic acid bacteria combination and compositions thereof
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
GB0323039D0 (en) 2003-10-01 2003-11-05 Danisco Method
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
WO2007140613A1 (en) 2006-06-06 2007-12-13 Mcgill University Fermented milk product and use thereof
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
RU2473681C2 (ru) 2007-03-28 2013-01-27 Элиментари Хелт Лимитед ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ТАКОЙ ШТАММ, И ЕГО ПРИМЕНЕНИЕ
RU2466185C2 (ru) 2007-03-28 2012-11-10 Элиментари Хелт Лимитед ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, ПРОБИОТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЯ ШТАММА Bifidobacterium longum
EP1997907A1 (en) 2007-06-01 2008-12-03 Friesland Brands B.V. Bifidobacteria
HUP0700552A2 (en) 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
ES2431572T3 (es) 2007-10-20 2013-11-27 Université de Liège Especies bifidobacterianas
WO2009149149A1 (en) 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
RU2546251C2 (ru) 2009-11-11 2015-04-10 Алиментари Хелс Лимитед Пробиотический штамм бифидобактерий
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
EP3033091B1 (en) 2013-08-16 2022-09-07 Versitech Limited Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma
WO2015038731A1 (en) 2013-09-12 2015-03-19 The Johns Hopkins University Biofilm formation to define risk for colon cancer
EP2876167A1 (en) 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
KR102735818B1 (ko) 2015-01-23 2024-11-28 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암 예방에서 단쇄 지방산의 용도
WO2016172658A2 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Microbiome regulators and related uses thereof
EP3964234A1 (en) 2015-04-23 2022-03-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
MD3650033T2 (ro) 2015-06-15 2022-08-31 4D Pharma Res Ltd Compoziții conţinând tulpini bacteriene
CN106110322A (zh) * 2016-07-29 2016-11-16 安徽瀚海博兴生物技术有限公司 一种药物组合物及其在制备治疗癌症药物中的应用
TW201906620A (zh) 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517425A (ja) 2013-03-14 2016-06-16 セラバイオーム，エルエルシー プロバイオティクス生物及び／又は治療剤の標的化胃腸管デリバリー
JP2017514857A (ja) 2014-05-05 2017-06-08 ジョヴァンニ・モーニャＧｉｏｖａｎｎｉ ＭＯＧＮＡ 腫瘍、後天性免疫不全症候群および白血病の二重免疫バイオスティミュレーションによる処置における使用のための治療剤
CN104224851A (zh) 2014-08-15 2014-12-24 任发政 动物双歧杆菌乳酸亚种CGMCC No.9273的应用
WO2016196605A1 (en) 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Int.J.Syst.Evol.Microbiol.，2004年，54，pp.1137-1143

Also Published As

Publication number Publication date
CA3068757A1 (en) 2019-01-10
AR112328A1 (es) 2019-10-16
US20190192585A1 (en) 2019-06-27
BR112019028301A2 (pt) 2020-07-14
US10576111B2 (en) 2020-03-03
KR20200024911A (ko) 2020-03-09
US20190224253A1 (en) 2019-07-25
MA51770A (fr) 2020-05-13
US20210093680A1 (en) 2021-04-01
TW201906620A (zh) 2019-02-16
AU2018298087A1 (en) 2020-01-23
CN111356464A (zh) 2020-06-30
JP2020526581A (ja) 2020-08-31
KR102563191B1 (ko) 2023-08-02
WO2019010255A1 (en) 2019-01-10
EP3648780A1 (en) 2020-05-13
US10792314B2 (en) 2020-10-06

Similar Documents

Publication Publication Date Title
US10576111B2 (en) Method of treating cancer using Bifidobacterium animalis ssp. lactis strain PTA-125097
JP7402805B2 (ja) ベイロネラ（Ｖｅｉｌｌｏｎｅｌｌａ）の細菌を使用して癌及び免疫障害を処置するための組成物及び方法
US20190314427A1 (en) Methods of treating cancer using parabacteroides
TWI814739B (zh) 細菌胞外囊泡
WO2018112365A2 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
US20210113628A1 (en) Intracellular delivery of biomolecules to modify immune response
CN111601610A (zh) 使用布劳特氏菌属菌株治疗疾病的组合物和方法
CN111712260A (zh) 使用毛螺菌科细菌治疗免疫病症的组合物和方法
CN111787932A (zh) 使用免疫调节性乳球菌属细菌菌株治疗免疫病症的组合物和方法
EP3570857A1 (en) Methods of treating cancer
EP3570856A2 (en) Methods of treating cancer
EP3982986A1 (en) Secreted microbial extracellular vesicles
US11241461B2 (en) Treating cancer using a blautia strain
WO2021022110A1 (en) Inducing immune effects using bacteria of the genus bifidobacterium
WO2019178494A1 (en) Compositions and methods for treating cancer and inflammation using tyzzerella nexilis
WO2019178490A1 (en) Compositions and methods for treating cancer and inflammation using klebsiella oxytoca
WO2019178055A1 (en) Extracellular vesicles from burkholderia
WO2019178487A2 (en) Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
WO2019169160A1 (en) Compositions and methods for treating cancer using ruminococcus gnavus
WO2019169168A1 (en) Compositions and methods for treating cancer using agathobaculum
WO2019169181A1 (en) Compositions and methods for treating cancer using lactobacillus salivarius
WO2019075452A1 (en) IDENTIFICATION OF BACTERIA FOR CANCER THERAPY
WO2019169143A1 (en) Compositions and methods for treating cancer using turicibacter sanguinis
WO2019169138A1 (en) Compositions and methods for treating cancer using paraclostridium benzoelyticum
WO2020006216A1 (en) Compositions and methods of treating cancer using neisseria bacteria

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210705

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230329

R150 Certificate of patent or registration of utility model

Ref document number: 7254786

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157